Lumosa Therapeutics Announces Positive Result from LT3001 Phase 2A Clinical Trial in Acute Ischemic Stroke

LT3001 represents a completely novel drug design in stroke treatment -- combining thrombolytic and neuroprotective properties into a single molecule which may confer unique efficacy and safety properties permitting a brand new perspective to the AIS patients.　

Lumosa and DONGWHA Enter Exclusive Distributorship Agreement for LT1001 in Korea – Securing a Foot in Northeast Asia and Increase Global Licensing Value

Formulation Patent for LT1001, An Extended-Release Analgesic Injection, Granted by Chinese Patent Office

Lumosa and Darnitsa Enter into Distribution Agreement in Ukraine for LT1001, an Extended-Release Analgesic Injection

(May 25th, 2021, Taipei) Lumosa Therapeutics is pleased to announce today the execution of an exclusive distribution agreement with PrJSC Pharmaceutical Firm Darnitsa (“Darnitsa”) for LT1001 in Ukraine. Darnitsa is one of the largest pharmaceutical companies in Ukraine. The company develops, manufactures, and markets generic, prescription, and over-the-counter products in several therapeutic areas including pain management. According to the agreement, Darnitsa is responsible for the registration, sales, and marketing of LT1001 in Ukraine, and Lumosa will supply LT1001 drug product. Lumosa is looking forward to working with Darnitsa to bring this unique product to the Ukrainian analgesic market, as well as gaining possible access to the Eastern European countries and Commonwealth of Independent States. 

LT3001 Compound Patent Approved in Korea and Europe

Patents Approved in South Korea and European Countries for Lumosa's Novel Treatment for Acute Ischemic Stroke Encouraging Global Patent Position and Advancements in Clinical Studies

Naldebain Approved by Singapore HSA

Lumosa is pleased to announce the market approval of LT1001 (Naldebain®), an extended-release analgesic injection, from Singapore’s Health Science Agency (HSA). Being one of the regulatory reference countries, HSA's approval has significance in accelerating the marketing of LT1001 in the rest of ASEAN member states. Applications for drug approval were also submitted to the health authorities of other Southeast Asian countries such as Malaysia and Thailand. Applications to the rest of ASEAN countries will soon follow.